Hospital Infection Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: June 19, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 11.10 billion |
|
Revenue Forecast in 2031 |
US$ 13.86 billion |
|
CAGR |
2.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hospital infection therapeutics market was valued at US$ 11.10 billion in 2022 and is expected to register a revenue CAGR of 2.5% to reach US$ 13.86 billion by 2031.
Hospital Infection Therapeutics Market Fundamentals
Hospital infection, also known as healthcare-associated infection (HAI) or nosocomial infection, refers to an infection acquired by a patient during the course of receiving medical care in a hospital or healthcare facility. These infections can occur due to various factors, including invasive procedures, exposure to contaminated medical equipment, contact with healthcare workers or other patients carrying infectious agents, and compromised immune systems of patients. Hospital infection therapeutics refer to the medical treatments and interventions to manage and treat infections acquired by patients within a hospital setting. The goal of hospital infection therapeutics is to prevent, control, and treat these infections, which can occur due to various factors such as invasive medical procedures, weakened immune systems of patients, antibiotic-resistant bacteria, and the close proximity of patients with infectious diseases.
Hospital Infection Therapeutics Market Dynamics
hospital-acquired infections (HAIs) are a major concern for healthcare facilities worldwide. The rising number of HAIs, such as surgical site infections, bloodstream infections, and pneumonia, drives the hospital infection therapeutics market demand. According to the WHO, out of every 100 patients in acute-care hospitals, 7 patients in high-income countries and 15 patients in low- and middle-income countries acquire at least one healthcare-associated infection (HAI) during their hospital stay. On average, 1 out of every 10 affected patients would die as a result of their HAI. The emergence of antibiotic-resistant bacteria poses a significant threat to public health. Antibiotic-resistant infections are more difficult to treat and can lead to increased mortality rates. This has created a need for new therapeutics and treatment strategies to combat these infections, driving the demand for innovative hospital infection therapeutics. The hospital infection therapeutics market outlook is positive as advancements in medical technology and therapeutics have led to the development of innovative solutions for hospital infections. These include novel antimicrobial agents, advanced disinfection systems, and improved diagnostic tools for early detection and prevention of infections. Increasing awareness about HAIs and their impact on patient outcomes has led to a greater focus on infection prevention and control. Educational initiatives and awareness campaigns by healthcare organizations, government bodies, and non-profit organizations have raised awareness among healthcare providers and patients about the importance of infection control measures, thereby driving the hospital infection therapeutics market growth.
However, the regulatory landscape for hospital infection therapeutics is complex and often stringent. The approval process for new drugs and treatment modalities involves rigorous testing, clinical trials, and compliance with regulatory guidelines, which is restricting the growth of the hospital infection therapeutics market. The research and development costs associated with developing new infection therapeutics can be substantial. The investment required to bring a new drug to market is significant from discovery to clinical trials, thus cramping the hospital infection therapeutics market growth.
Hospital Infection Therapeutics Market Ecosystem
The global hospital infection therapeutics market is analyzed from three perspectives: drug class, indication, and region.
Hospital Infection Therapeutics Market by Drug Class
Based on the drug class, the global hospital infection therapeutics market is segmented into anti-fungal drugs, antiviral drugs, antibacterial drugs, and others.
The antibacterial drugs segment accounted for the prominent hospital infection therapeutics market share in 2022, with a 66% market share. Bacterial infections are one of the most common types of hospital-acquired infections. Antibacterial drugs are specifically designed to target and kill bacteria or inhibit their growth, making them a primary treatment option for bacterial infections. Antibiotic resistance is a significant global concern. The rise of multidrug-resistant bacteria has limited the effectiveness of many existing antibiotics. Despite this challenge, antibacterial drugs remain crucial in treating infections caused by susceptible bacteria. Antibacterial drugs can have a broad spectrum of activity, meaning they are effective against a wide range of bacterial pathogens. This versatility allows them to target and treat various types of infections caused by different bacteria. Despite the challenges of antibiotic resistance, there is ongoing research and development in antibacterial drugs. Pharmaceutical companies are developing new antibiotics, combination therapies, and modified formulations to overcome resistance and improve efficacy. This ongoing innovation ensures a steady stream of new antibacterial drugs entering the market, further contributing to the growth of this segment.
Hospital Infection Therapeutics Market by Indication
Based on the indications, the global hospital infection therapeutics market is segmented into ventilator-associated pneumonia, surgical site infections, urinary tract infections, bloodstream infections, and others.
The surgical site infections segment accounted for the largest revenue share of the hospital infection therapeutics market, with a 30.6% market share. Surgical site infections are a common type of hospital-acquired infection, accounting for a significant proportion of healthcare-associated infections. Surgical site infections occur after a surgical procedure, leading to complications, prolonged hospital stays, increased healthcare costs, and patient morbidity. The high incidence of surgical site infections drives the demand for therapeutics specifically to prevent and treat these infections. According to the CDC, surgical site infections account for 20% of all HAIs and are associated with a 2- to 11-fold increase in mortality risk, with 75% of surgical site infections-related deaths being directly attributable to surgical site infections. Surgical site infections can range from superficial infections to deep and organ/space infections. Deep and organ/space infections are more severe, can involve deeper tissues or internal organs, and are associated with higher morbidity and mortality rates. Regulatory bodies and healthcare organizations place significant emphasis on preventing surgical site infections. They have developed guidelines and protocols for infection prevention during surgical procedures, including the use of prophylactic antibiotics. Compliance with these guidelines drives the demand for infection therapeutics designed for surgical site infections.
Surgical site infections have substantial economic implications for healthcare systems. They result in increased healthcare costs due to prolonged hospital stays, additional diagnostic tests, increased use of antibiotics, and the need for additional surgical interventions or wound care. According to the CDC, with an estimated yearly cost of US$3.3 billion, surgical site infections are the most expensive HAI type in the U.S., extending hospital length of stay by 9.7 days and increasing hospitalization costs by more than $20,000 for each admission. The economic burden associated with surgical site infections creates a demand for effective therapeutics that can reduce the incidence and severity of these infections. In recent years, there has been an increased focus on infection prevention and control in surgical settings. Healthcare facilities are implementing strict hand hygiene practices, proper sterilization techniques, and antimicrobial sutures or dressings to prevent surgical site infections. The demand for infection therapeutics is driven by the need to complement these preventive measures and effectively manage surgical site infections when they occur.
Hospital Infection Therapeutics Market by Region
Geographically, the global hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest hospital infection therapeutics market size in terms of revenue generation accounting for around 34.5% share of the market. HAIs are a significant concern in North America, leading to increased morbidity, mortality, and healthcare costs. The high prevalence of HAIs drives the demand for effective therapeutics to prevent and treat these infections. According to the CDC, an estimated 1 in every 31 hospital patients and 1 in every 43 nursing care residents has HAI. Furthermore, the CDC estimates that on any given day, approximately half of hospital patients and 1 in every 12 nursing care residents receive antimicrobial medicine. There is an increasing awareness among healthcare providers and the general public about the impact of HAIs on patient outcomes. Educational initiatives and awareness campaigns by healthcare organizations, government agencies, and patient advocacy groups have raised awareness about the importance of infection prevention and control. North America has a well-established healthcare infrastructure with advanced healthcare facilities and a high standard of care. This enables healthcare providers to adopt and implement infection control measures and invest in effective therapeutics, which is also boosting regional growth.
Hospital Infection Therapeutics Market Competitive Landscape
The prominent players operating in the global hospital infection therapeutics market are:
Hospital Infection Therapeutics Market Strategic Developments
Hospital infection, also known as healthcare-associated infection (HAI) or nosocomial infection, refers to an infection acquired by a patient during the course of receiving medical care in a hospital or healthcare facility.
Asia Pacific is the key growth region in the global market during the forecast period from 2023 to 2031.
Collaboration and partnerships are common strategies in the hospital infection therapeutics market. Key players are collaborating with research institutions, academic organizations, and other pharmaceutical companies to pool resources, share expertise, and accelerate the development of new therapeutics.
The global hospital infection therapeutics market growth is estimated to grow at a revenue CAGR of 2.5% during the forecast period from 2023 to 2031.
The estimated size of the global hospital infection therapeutics market in 2031 is US$ 13.86 billion.
*Insights on financial performance are subject to the availability of information in the public domain